Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories established Pharmaceutical Products — Segment Total Assets ($M) ($M)
Postgres DB segment_values + Form 10-K/10-Q XBRL
Latest, Q2 2026
3,819
Period ended Jun 30, 2026
Change on a year earlier
+2.3%
3,732 in Q2 2025
History
25 quarters
Since Q4 2009
Sources
22
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Established Pharmaceutical Products — Segment Total Assets ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 3,819 | +2.3% | Form 10-Q (filed 2026-07-28) ↗ |
| Q1 2026 | Mar 31, 2026 | 3,665 | +6.3% | Form 10-Q (filed 2026-04-29) ↗ |
| Q4 2025 | Dec 31, 2025 | 3,540 | +14.7% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 3,730 | – | Form 10-Q (filed 2025-10-29) ↗ |
| Q2 2025 | Jun 30, 2025 | 3,732 | – | Form 10-Q (filed 2025-07-30) ↗ |
| Q1 2025 | Mar 31, 2025 | 3,448 | – | Form 10-Q (filed 2025-04-30) ↗ |
| Q4 2024 | Dec 31, 2024 | 3,087 | -1.0% | Form 10-K (filed 2025-02-21) ↗ |
| Q4 2023 | Dec 31, 2023 | 3,118 | +8.2% | Form 10-K (filed 2024-02-16) ↗ |
| Q4 2022 | Dec 31, 2022 | 2,883 | +3.4% | Form 10-K (filed 2023-02-17) ↗ |
| Q4 2021 | Dec 31, 2021 | 2,789 | -3.4% | Form 10-K (filed 2022-02-18) ↗ |
| Q4 2020 | Dec 31, 2020 | 2,888 | +1.0% | Form 10-K (filed 2021-02-19) ↗ |
| Q4 2019 | Dec 31, 2019 | 2,858 | +7.3% | Form 10-K (filed 2020-02-21) ↗ |
| Q4 2018 | Dec 31, 2018 | 2,664 | -2.3% | Form 10-K (filed 2019-02-22) ↗ |
| Q4 2017 | Dec 31, 2017 | 2,728 | +9.7% | Form 10-K (filed 2018-02-16) ↗ |
| Q4 2016 | Dec 31, 2016 | 2,486 | +12.5% | Form 10-K (filed 2017-02-17) ↗ |
| Q4 2015 | Dec 31, 2015 | 2,210 | -1.5% | Form 10-K (filed 2016-02-19) ↗ |
| Q4 2014 | Dec 31, 2014 | 2,244 | +55.3% | Form 10-K (filed 2015-02-27) ↗ |
| Q4 2013 | Dec 31, 2013 | 1,445 | +4.6% | Form 10-K (filed 2015-02-27) ↗ |
| Q3 2013 | Sep 30, 2013 | 2,600 | – | Form 10-Q (filed 2013-11-07) ↗ |
| Q2 2013 | Jun 30, 2013 | 2,500 | – | Form 10-Q (filed 2013-08-06) ↗ |
| Q1 2013 | Mar 31, 2013 | 2,600 | – | Form 10-Q (filed 2013-05-08) ↗ |
| Q4 2012 | Dec 31, 2012 | 1,382 | -68.2% | Form 10-K (filed 2015-02-27) ↗ |
| Q4 2011 | Dec 31, 2011 | 4,348 | -35.4% | Form 10-K (filed 2014-02-21) ↗ |
| Q4 2010 | Dec 31, 2010 | 6,730 | +170.3% | Form 10-K (filed 2012-02-21) ↗ |
| Q4 2009 | Dec 31, 2009 | 2,490 | – | Form 10-K (filed 2012-02-21) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Established Pharmaceutical Products — Segment Total Assets ($M) ($M), quarterly Q4 2009–Q2 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/db-seg-assets-epd
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.